Open AccessAstragalus polysaccharide attenuates LPS‐related inflammatory osteolysis by suppressing osteoclastogenesis by reducing the MAPK signalling pathway
Author(s) -
Yang Jianye,
Qin Leilei,
Huang Jiaxing,
Li Yuwan,
Xu Sha,
Wang Hai,
Zhu Sizheng,
Wang Jiawei,
Zhu Bo,
Li Feilong,
Huang Wei,
Gong Xuan,
Hu Ning
Publication year - 2021
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.16683
Subject(s) - osteoclast , osteolysis , rankl , cathepsin k , mapk/erk pathway , in vivo , cancer research , p38 mitogen activated protein kinases , nf κb , chemistry , inflammation , microbiology and biotechnology , immune system , immunology , in vitro , signal transduction , medicine , biology , biochemistry , activator (genetics) , surgery , gene
Abstract Bacterial products can stimulate inflammatory reaction and activate immune cells to enhance the production of inflammatory cytokines, and finally promote osteoclasts recruitment and activity, leading to bone destruction. Unfortunately, effective preventive and treatment measures for inflammatory osteolysis are limited and usually confuse the orthopedist. Astragalus polysaccharide (APS), the main extractive of Astragali Radix, has been widely used for treating inflammatory diseases. In the current study, in vitro and in vivo experimental results demonstrated that APS notably inhibited osteoclast formation and differentiation dose‐dependently. Moreover, we found that APS down‐regulated RANKL‐related osteoclastogenesis and levels of osteoclast marker genes, such as NFATC1 , TRAP , c‐FOS and cathepsin K. Further underlying mechanism investigation revealed that APS attenuated activity of MAPK signalling pathways (eg ERK, JNK and p38) and ROS production induced by RANKL. Additionally, APS was also found to suppress LPS‐related inflammatory osteolysis by decreasing inflammatory factors' production in vivo. Overall, our findings demonstrate that APS effectively down‐regulates inflammatory osteolysis due to osteoclast differentiation and has the potential to become an effective treatment of the disorders associated with osteoclast.